BIOMERIEUX SA

bioMérieux is a global in vitro diagnostics leader headquartered in France, with significant US operations. The company manufactures and distributes comprehensive diagnostic solutions for clinical microbiology, molecular pathology, blood culture detection, immunoassays, and rapid point-of-care testing. Core competencies span microbial identification and antimicrobial susceptibility testing (ID/AST), sepsis diagnosis and management, infectious disease detection (respiratory pathogens, gastrointestinal pathogens), and blood culture systems. Key product platforms include BIOFIRE® FILMARRAY® multiplex PCR systems, VITEK® MS PRIME mass spectrometry, BACT/ALERT® VIRTUO® blood culture automation, and VIDAS® immunoassay analyzers. The company also serves pharmaceutical and food safety markets with quality control and environmental monitoring solutions. bioMérieux addresses critical clinical challenges including antimicrobial resistance (AMR) stewardship, rapid sepsis identification, and respiratory infection diagnostics. Offerings span hospital laboratories, point-of-care settings, and industrial applications. The company emphasizes diagnostic-driven clinical decision support, workflow automation, and integrated laboratory information management. Manufacturing includes automated detection systems, rapid molecular platforms, and MALDI-TOF mass spectrometry instruments. US operations distribute test kits, reagents, and instruments through multiple channels including direct sales and the bioMérieux eShop. The company holds multiple regulatory clearances including FDA 510(k) approvals and CE marking for diagnostic instruments and test kits.